Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Linde PLC (LIN) vs Viatris Inc (VTRS) Price & Performance

Viatris IncTrade

Price performance (Past 24H)

Key statistics

Linde PLC vs Viatris Inc — how do they compare? Linde PLC trades at $483.73 (market cap $222.05B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Linde PLC is far larger — about 11.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Viatris Inc for 57 Days on average.

LINVTRS
Market Cap
$222.05B$20.03B
Volume
2,116,44014,109,977
Sector
Basic MaterialsHealth
52-Week High
$546.64$18.27
52-Week Low
$389.38$9.74
Typical Hold Time
88 Days57 Days
Enterprise Value
$245.17B$32.15B
Dividend Yield
1.33%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Linde PLC

Linde (LIN) trades at $481.70, down 0.47% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $4.50 beating estimates of $4.49, and maintains healthy profitability with a 20.43% net income margin. Analyst sentiment remains overwhelmingly positive with 89.66% buy ratings and a $557.10 consensus price target representing 15.6% upside potential from current levels.

The outlook remains favorable given Linde's leadership in industrial gases and exposure to AI chip manufacturing growth, though valuation at 31.08 P/E requires continued execution. Key risks include margin pressure from higher capital expenditures and competitive dynamics in the electronics sector. The stock's technical setup suggests support near $479 with resistance at $485, providing clear levels for near-term price action.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.

The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LIN
0% Buy100% Sell
Avg holding period · 88 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →